Accelence Announces Venture Partnership With PharmaNest to Support US Commercialization

Accelence is pleased to announce a partnership with PharmaNest, a contract operations organization who commercializes breakthrough International IND-Enabling Technologies and Services for the US Markets.

PRINCETON, NJ (I-Newswire) August 4, 2012 - Accelence is pleased to announce a partnership with PharmaNest , a contract operations organization who commercializes breakthrough International IND-Enabling Technologies and Services for the US Markets.

Accelence fulfills increasing CRO and industry sponsor requirements to boost patient inclusion rates and speed up phase II to phase IV tests, while ensuring compliance with all quality standards. A first in Europe, founded upon a wide-ranging consensus between industrial, hospital and academic environments, Accelence has taken on the following objectives:

- Achieving higher patient inclusion rates in the operation of high-potential industry-sponsored clinical trials;
- Liaising between industry sponsors and investigation sites as a one-stop solution, and streamlining procedures to increase efficiency and reduce leadtime on trials;
- Optimizing patient enrolment by implementation of a practitioners’ network in close collaboration with hospital investigation sites.

“Accelence network of qualified clinical sites and world-renowned Key Opinion Leaders has the capability to help US Pharmaceutical Companies and Clinical research Organization to improve the speed and relevance of clinical trial feasibility studies and, later, execute trials with a focus on quality and effective patient recruitment. Our ecosystems gives access to more than 250,000 patients per year and our expertise is recognized in Oncology, Neurology, Cardiovascular and Orthopedic, with centers of excellence in Medical Devices, Core Lab Imaging, Parkinson Disease, Senior Oncology Care” says Patrick Varache, Managing Director of Accellence.

“Accelence brings a solution that most pharmaceutical companies and CROS are seeking, and we are confident that PharmaNest will be the catalyst for several strategic partnership will leading clinical research industry players in 2013” says Mathieu Petitjean, Ph.D, CEO of PharmaNest.

PharmaNest experienced team is joining Accelence team to provide a larger visibility of the services in North America.

About Accelence
Accelence is a combination of the assets and skills of its 4 founding entities: the BORDEAUX UNIVERSITY HOSPITAL, the BERGONIÉ INSTITUTE (Regional Cancer Center), BORDEAUX SEGALEN UNIVERSITY and the INDUSTRIAL RESEARCH SUPPORT COMPANY (SARI). Founded on the initiative of the Bordeaux Chamber of Commerce and Industry, SARI brings together twelve local SMEs in the relevant sectors (pharmaceuticals, medical devices, nutrition). For industry sponsors and CROs both in France and abroad, Accelence is the solution for easy access to a significant number of potential patients over a wide range of therapeutic fields within the conduct of clinical trials in the Bordeaux region-France.